Liposomic drug-delivery vehicles
A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises: a) at least one bilayer-forming lipid; b) a polymeric compound having the general formula I: wherein m, n, L, X, Y, and Z are as defined herein; and c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.
1 . A method of treating a synovial joint disorder in a subject in need thereof, the method comprising administering to the subject a liposome comprising:
a) at least one bilayer-forming lipid;
b) a polymeric compound having the general formula I:
wherein:
m is zero or a positive integer;
n is an integer which is at least 3;
Y is a backbone unit which forms a polymeric backbone;
L is absent or is a linking moiety; and
Z has the general formula II:
wherein:
A is a substituted or unsubstituted hydrocarbon;
B is an oxygen atom;
R 1 -R 3 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroalicyclic, aryl and heteroaryl; and
X is a lipid moiety having the general formula III:
wherein:
W 1 and W 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl and acyl, wherein at least one of W 1 and W 2 is not hydrogen;
J is —P(═O)(OH)—O— or absent;
K is a substituted or unsubstituted hydrocarbon from 1 to 10 carbon atoms in length, or absent;
M is a linking group selected from the group consisting of —O—, —S—, amino, sulfinyl, sulfonyl, phosphate, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, urea, thiourea, carbamyl, thiocarbamyl, amido, carboxy, and sulfonamide, or absent; and
Q is a substituted or unsubstituted hydrocarbon from 1 to 10 carbon atoms in length,
wherein when M is absent, K is also absent; and
c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome, said therapeutically active agent being selected from an analgesic, an anti-inflammatory agent, an anti-proliferative agent, an anti-microbial agent, and a vaccine antigen,
thereby treating the synovial joint disorder.
2 . The method according to claim 1 , wherein said therapeutically active agent is selected from the group consisting of an analgesic, an anti-inflammatory agent and an anti-microbial agent.
3 . The method according to claim 1 , wherein said administering is by parenteral systemic administration.
4 . The method according to claim 1 , wherein administering is by intra-articular administration.
5 . The method according to claim 1 , wherein said synovial joint disorder is selected from the group consisting of arthritis, bursitis, carpal tunnel syndrome, fibromyositis, gout, locked joint, tendinitis, traumatic joint injury, and joint injury associated with surgery.
6 . The method according to claim 1 , wherein Y is a substituted or unsubstituted alkylene unit.
7 . The method according to claim 6 , wherein Y has the formula —CR 4 R 5 —CR 6 D-, wherein:
when Y is a backbone unit which is not attached to said L or said Z, D is R 7 ; and when Y is a backbone unit which is attached to said L or said Z, D is a covalent bond or a linking group attaching Y to said L or said Z, said linking group being selected from the group consisting of —O—, —S—, alkylene, arylene, sulfinyl, sulfonyl, phosphate, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino; and
R 4 -R 7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, azo, phosphate, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino.
8 . The method according to claim 7 , wherein said linking group is selected from the group consisting of —O—, —C(═O)O—, —C(═O)NH— and phenylene.
9 . The method according to claim 7 , wherein L is a substituted or unsubstituted hydrocarbon from 1 to 10 carbon atoms in length.
10 . The method according to claim 1 , wherein A is a substituted or unsubstituted hydrocarbon from 1 to 4 carbon atoms in length.
11 . The method according to claim 1 , wherein at least a portion of said Y, said L and/or said Z comprises at least one targeting moiety.
12 . The method according to claim 1 , wherein said lipid is selected from the group consisting of a fatty acid, a monoglyceride, a diglyceride, a triglyceride, a glycerophospholipid, a sphingolipid, and a sterol.
13 . The method according to claim 1 , wherein J is —P(═O)(OH)—O— and K is selected from the group consisting of an ethanolamine moiety, a serine moiety, a glycerol moiety and an inositol moiety.
14 . The method according to claim 1 , wherein M is amido.
15 . The method according to claim 1 , wherein J and K are absent and M is carbonyl.
16 . The method according to claim 1 , wherein Q is dimethylmethylene (—C(CH 3 ) 2 —).
17 . The method according to claim 1 , wherein at least one of W 1 and W 2 is alkyl, alkenyl, alkynyl or acyl, being from 10 to 30 carbon atoms in length.
18 . The method according to claim 1 , wherein said lipid moiety comprises at least one fatty acid moiety selected from the group consisting of lauroyl, myristoyl, palmitoyl, stearoyl, palmitoleoyl, oleoyl, and linoleoyl.
19 . The method according to claim 1 , wherein said liposome is formulated as part of a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier.
20 . The method according to claim 19 , wherein said carrier comprises an aqueous liquid.
21 . The method according to claim 19 , wherein said pharmaceutical composition further comprises a water-soluble biopolymer.